查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924687

KRAS抑制劑市場依適應症、作用機制、突變類型、劑型、最終用戶和通路分類－2026-2032年全球預測

KRAS Inhibitor Market by Indication, Mechanism Of Action, Mutation Type, Dosage Form, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

KRAS抑制劑市場預計到2025年將達到9.2385億美元，到2026年將成長到9.6858億美元，到2032年將達到12.7767億美元，年複合成長率為4.74%。

關鍵市場統計數據
基準年 2025 9.2385億美元
預計年份：2026年 9.6858億美元
預測年份 2032 1,277,670,000 美元
複合年成長率 (%) 4.74%

展望未來，概述KRAS抑制劑的科學突破、臨床路徑、監管環境和策略重點。

經過數十年的科學挑戰，KRAS抑制已成為標靶癌症治療創新的重點。結構生物學的最新進展、藥物發現平台的改進以及更具預測性的臨床前模型，使得治療方法能夠選擇性地靶向致癌性的KRAS突變，從而改變了臨床醫生和研發人員應對傳統上難以治療的癌症促進因素的方式。隨著該領域的不斷發展，相關人員必須權衡加速的轉化研究進展與臨床異質性、支付方審查以及複雜的生產要求等現實因素。

深入剖析KRAS抑制劑的研發、商業性趨勢、試驗設計、夥伴關係模式以及重塑病患用藥路徑的變革性轉變

KRAS抑制劑領域正經歷著由科學、臨床和商業性發展融合驅動的變革性轉折點。首先，針對突變特異性結合位點的精準設計方法正在加速化合物從發現階段轉換到人體試驗的過程。同時，與免疫療法和路徑調節劑的聯合策略正在重新定義試驗終點和隊列選擇。因此，申辦方正迅速轉向適應性試驗設計，這種設計能夠基於中間生物標記進行決策並富集隊列，從而加快獲得具有臨床意義的結果。

深入分析2025年美國關稅和貿易政策變化對KRAS抑制劑供應鏈、生產和定價趨勢的影響

2025年源自美國的貿易政策變化和關稅措施可能透過一系列營運和策略途徑對KRAS抑制劑生態系統產生重大影響。關稅調整若導致進口活性藥物原料藥、特殊試劑或關鍵生產設備的成本增加，可能會擠壓利潤空間，並促使關鍵生產環節回流至國內或近岸地區。為此，申辦方和契約製造製造商可能會加快本地化策略，重新評估供應商選擇計劃，並優先考慮雙重採購以降低關稅和物流風險。

從臨床、機制、突變、劑量、終端用戶和管道等觀點，揭示治療方法差異化和推廣應用的策略性細分洞察。

有效的市場區隔對於將科學差異轉化為有針對性的開發和商業化路徑至關重要。必須了解大腸直腸癌、非小細胞肺癌和動態的市場動態，因為腫瘤生物學、治療前環境和診斷流程會影響不同適應症的臨床試驗實施和應用考量。根據作用機制，變構抑制劑、共用抑制劑和非共用抑制劑提供了不同的治療方法，每種方法都有獨特的安全性、給藥策略和抗藥性模式。根據突變類型，項目重點與G12C、G12D和G12V等關鍵促進因素一致，而突變特異性療效則決定了伴隨診斷策略和患者族群選擇方法。

影響臨床試驗、監管方式和病患准入的區域趨勢：來自美洲、歐洲、中東和非洲以及亞太地區的亮點

區域差異對研發時間表、監管互動和市場准入途徑有顯著影響。在美洲，臨床試驗能力、完善的支付方體系和大規模的腫瘤網路使得基於生物標記篩選的患者隊列能夠快速招募，而報銷談判和衛生技術評估（HTA）的參與則對上市順序和市場准入政策產生重大影響。在歐洲、中東和非洲，不同的監管標準、國家報銷體系和診斷基礎設施要求研發企業制定適應性強的打入市場策略，以適應區域性的HTA流程、共同支付結構和不同的臨床證據要求。在亞太地區，多個市場的快速核准通道、不斷擴展的精準診斷基礎設施以及日益成長的腫瘤治療能力既帶來了機遇，也帶來了挑戰。研發企業必須調整其申報策略和本地臨床項目，以適應不同的核准途徑和支付方標準。

公司層面視角：對KRAS專案的競爭定位、研發管線重點、合作夥伴關係、生產能力及商業化準備進行分析

公司層面的趨勢是KRAS抑制劑近期市場發展的關鍵促進因素。主要企業正透過聚焦產品線、最佳化藥物化學方法以提高選擇性和安全性，以及建立策略聯盟來加速與聯合治療合作夥伴和診斷能力的對接，從而實現差異化競爭。一些公司正在投資擴大生產規模和簽訂長期原料藥供應協議，以確保可靠的臨床供應並為潛在的商業需求做好準備。另一些公司則優先採用精益外包模式，以保持柔軟性並降低資本風險。

為產業領導者提供切實可行的建議，以加速KRAS開發、完善商業策略、儘早與支付方接洽並增強供應韌性。

行業領導者必須採取務實且優先的行動，將科學進步轉化為對患者的持久影響。首先，將轉化科學和臨床試驗設計與明確的監管和支付方證據要求一致，並進行能夠產生有利於醫保報銷決策所需數據的研究。其次，實施穩健的供應鏈連續性計劃，包括雙重採購、本地生產評估和檢驗的應急庫存水平，以降低地緣政治和關稅相關風險。第三，促進與支付方的早期務實溝通，以確定價值來源、明確可接受的終點指標，並探索能夠在整個價值鏈上共用風險的創新合約模式。

一套透明的調查方法，詳細說明了資料收集方法、證據綜合、相關人員訪談、臨床試驗映射和品質保證通訊協定。

本報告的分析遵循透明的調查方法，整合多方證據，以確保其可靠性和相關性。關鍵資訊來源包括同行評審文獻、公開的監管文件、臨床試驗註冊資訊以及有助於理解專案層面和機制的公司披露資訊。資訊來源，我們也對臨床研究人員、生產專家和商業領袖進行了結構化訪談，以了解實際營運和前瞻性觀點。在綜合這些資訊時，我們優先考慮由多個獨立資訊來源證實的資料點，並仔細進行交叉檢驗。

最終綜合分析，提煉出KRAS投資與策略的科學進展、臨床意義、商業化準備與策略要務。

總而言之，KRAS抑制劑的研發正處於一個轉折點，結構生物學的突破和精密的臨床策略正與商業性和營運的迫切需求交匯融合。科學進步使得針對特定突變的標靶化成為可能，但要真正造福患者，需要整合試驗設計、生產能力、醫保合作以及地域參與策略等各個環節。能夠成功駕馭這些相互關聯的領域的公司，將能夠把轉化醫學的進展轉化為永續的臨床項目和可及的治療方法。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：KRAS抑制劑市場（依適應症分類）

  • 大腸直腸癌
  • 非小細胞肺癌
  • 胰臟癌

9. KRAS抑制劑市場依作用機轉分類

  • 變構抑制劑
  • 共用抑制劑
  • 共用抑制劑

第10章 按突變類型分類的KRAS抑制劑市場

  • G12C
  • G12D
  • G12V

第11章 KRAS抑制劑市場按劑型分類

  • 注射液
  • 口服錠劑

第12章 KRAS抑制劑市場（依最終用戶分類）

  • 癌症治療中心
  • 醫院
  • 零售藥房
  • 專科診所

第13章 KRAS抑制劑市場（依通路分類）

  • 離線
  • 線上

第14章 KRAS抑制劑市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 KRAS抑制劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國KRAS抑制劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國KRAS抑制劑市場

第18章：中國KRAS抑制劑市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen
  • AnBogen Therapeutics
  • Applied Pharmaceutical Science
  • AstraZeneca
  • Biond Biologics
  • Boehringer Ingelheim
  • BridgeBio Oncology Therapeutics
  • Bristol Myers Squibb
  • Cardiff Oncology, Inc.
  • Deciphera Pharmaceuticals
  • Eli Lilly
  • Elicio Therapeutics
  • Erasca
  • Frontier Medicines
  • GenFleet Therapeutics
  • Gritstone Bio
  • Immuneering Corporation
  • Innovent Bio
  • InventisBio
  • Jacobio Pharmaceuticals
  • Jiangsu Hansoh Pharmaceutical
  • Jiangsu Hengrui Medicine Co.
  • Merck
  • Mirati Therapeutics
  • Novartis
  • Quanta Therapeutics
  • Revolution Medicines
  • Roche
  • Suzhou Zelgen Biopharmaceuticals
  • Verastem Oncology
Product Code: MRR-7A380DA7C427

The KRAS Inhibitor Market was valued at USD 923.85 million in 2025 and is projected to grow to USD 968.58 million in 2026, with a CAGR of 4.74%, reaching USD 1,277.67 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 923.85 million
Estimated Year [2026] USD 968.58 million
Forecast Year [2032] USD 1,277.67 million
CAGR (%) 4.74%

A forward-looking introduction that frames KRAS inhibitor scientific breakthroughs, clinical translation pathways, regulatory landscape and strategic priorities

KRAS inhibition has emerged from decades of scientific challenge to become a focal point for targeted oncology innovation. Recent structural biology advances, improved drug-design platforms and more predictive preclinical models have enabled therapies that selectively target oncogenic KRAS mutations, changing how clinicians and developers approach historically intractable cancer drivers. As the field advances, stakeholders must reconcile accelerated translational progress with the realities of clinical heterogeneity, payer scrutiny and complex manufacturing requirements.

This introduction positions the reader to understand the multifaceted forces shaping KRAS inhibitor development today. It highlights the interplay between molecular design choices and clinical strategy, clarifies how mutation-specific efficacy translates to indication prioritization, and outlines the key operational considerations that influence progression from early-phase trials to broader clinical adoption. By framing the science alongside commercial and regulatory considerations, this opening establishes a practical lens through which subsequent sections interpret supply-chain dynamics, segmentation nuances, regional differences and company-level competitiveness, enabling executives to align scientific opportunity with executable business plans.

An incisive review of transformative shifts reshaping KRAS inhibitor R&D, commercial dynamics, trial designs, partnership models and patient access pathways

The KRAS inhibitor landscape is experiencing transformative shifts driven by converging scientific, clinical and commercial developments. First, precision design approaches that exploit unique mutant pockets have accelerated the transition of compounds from discovery into human testing, while combination strategies with immunotherapies and pathway modulators are redefining trial endpoints and cohort selection. As a result, sponsors are moving faster to adaptive trial designs that allow for interim biomarker-driven decisions and enriched cohorts, thereby shortening the path to clinically meaningful readouts.

Concurrently, commercial dynamics are evolving: payers and health systems increasingly demand robust comparative-effectiveness evidence, and licensing and partnership models are shifting toward risk-sharing and milestone-based agreements to spread development burden and accelerate global access. Manufacturing and supply chain planning have become strategic differentiators, with developers investing in scalable API routes and redundant production nodes. Taken together, these shifts require organizations to integrate translational science with pragmatic go-to-market strategies, emphasize cross-functional coordination, and prioritize early dialogue with regulators and payers to de-risk late-stage development and enable sustainable patient access.

A nuanced analysis of how United States tariffs and trade policy changes in 2025 could affect KRAS inhibitor supply chains, manufacturing and pricing dynamics

Trade policy changes and tariff actions originating from the United States in 2025 can exert meaningful influence on the KRAS inhibitor ecosystem through a series of operational and strategic channels. Tariff adjustments that increase costs for imported active pharmaceutical ingredients, specialized reagents, or critical manufacturing equipment create pressure on margins and can incentivize onshoring or nearshoring of key manufacturing steps. In response, sponsors and contract manufacturers may accelerate localization strategies, revise supplier qualification plans, and prioritize dual-sourcing to mitigate tariff and logistics exposure.

Beyond direct cost impacts, tariff-driven reconfiguration of supply chains can affect timelines for CMO scale-up, capital deployment for domestic capacity, and inventory strategies to ensure clinical trial continuity. Indirect effects may include renegotiated partnership terms as externalized cost structures shift commercial models, and a renewed emphasis on upstream process innovations that reduce reliance on tariff-impacted inputs. Importantly, regulatory compliance and quality oversight remain non-negotiable during any supply-chain transition, so organizations must balance speed with quality assurance. Ultimately, prudent planning-rooted in scenario analysis, early supplier engagement, and contingency manufacturing agreements-can preserve development timelines and maintain patient access while navigating trade-policy headwinds.

Strategic segmentation insights revealing clinical, mechanistic, mutational, dosage, end-user and channel perspectives on therapeutic differentiation and adoption

Meaningful segmentation is essential for translating scientific differentiation into targeted development and commercialization pathways. Based on Indication, market dynamics must be understood across Colorectal Cancer, Non-Small Cell Lung Cancer, and Pancreatic Cancer where tumor biology, prior treatment landscapes and diagnostic routines create distinct trial and uptake considerations. Based on Mechanism Of Action, therapeutic approaches differ among Allosteric Inhibitors, Covalent Inhibitors, and Non-Covalent Inhibitors, each presenting unique safety profiles, dosing strategies and resistance patterns. Based on Mutation Type, program focus aligns to predominant drivers such as G12C, G12D, and G12V, and mutation-specific efficacy dictates companion diagnostic strategies and patient-enrichment methods.

Further granularity comes from dosage and delivery considerations: Based on Dosage Form, formulations such as Injectable Solutions versus Oral Tablets affect administration settings, adherence expectations and distribution logistics. Based on End User, channels vary across Cancer Care Centers, Hospitals, Retail Pharmacies, and Specialty Clinics, shaping provider training, infusion capacity requirements and patient support models. Finally, Based on Distribution Channel, the dynamics of Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Specialty Pharmacy influence stocking policies, reimbursement pathways and last-mile delivery strategies. Integrating these segmentation lenses enables a coherent view of how clinical attributes translate into operational priorities and commercial approaches.

Regional spotlight on Americas, Europe, Middle East & Africa and Asia-Pacific dynamics shaping clinical trials, regulatory approaches and patient access

Regional nuance shapes development timelines, regulatory interactions and access pathways in meaningful ways. In the Americas, clinical trial capacity, established payer frameworks and large oncology networks enable rapid patient recruitment for biomarker-selected cohorts, while reimbursement negotiations and HTA engagements strongly influence launch sequencing and access policies. In Europe, Middle East & Africa, the mosaic of regulatory standards, national reimbursement systems and variable diagnostic infrastructure requires adaptive market-entry strategies that account for regional HTA processes, co-pay structures and differentiated clinical evidence expectations. In Asia-Pacific, accelerated regulatory pathways in several markets, expanding precision-diagnostics infrastructure and growing oncology treatment capacity present both an opportunity and a complexity: developers must calibrate dossier strategies and local clinical programs to accommodate diverse approval pathways and payer criteria.

Cross-region considerations also influence supply and manufacturing footprints, as regional regulatory standards and import/export constraints shape location decisions and inventory planning. Consequently, a regionalized approach that aligns clinical evidence generation with local regulatory expectations, engages payers early, and invests in diagnostic and provider education will enhance adoption and ensure more predictable patient access across these distinct geographies.

Company-level perspectives unpacking competitive positioning, pipeline focus, alliances, manufacturing capability and commercialization readiness for KRAS programs

Company-level dynamics are central to how the KRAS inhibitor landscape will evolve over the near term. Leading developers are differentiating through focused pipelines, optimized medicinal chemistry approaches that improve selectivity and safety, and strategic collaborations that accelerate access to combination partners or diagnostic capabilities. Several firms are investing in scale-up capacity and long-term API supply agreements to ensure reliable clinical supply and prepare for potential commercial demand, while others prioritize lean outsourcing models to maintain flexibility and limit capital exposure.

Partnership strategies range from co-development and licensing to catalytic R&D alliances with diagnostics providers and academic centers, reflecting an emphasis on shared risk and complementary capabilities. Competitive positioning also depends on the depth of clinical data packages, the clarity of biomarker-driven value propositions, and proven manufacturing robustness. For investors and strategic planners, assessing company strength requires careful evaluation of pipeline breadth, clinical evidence quality, strategic alliances, production readiness and commercialization capabilities, recognizing that execution across these domains ultimately determines the ability to convert scientific promise into accessible therapies.

Actionable recommendations for industry leaders to accelerate KRAS development, refine commercial strategies, engage payers early and fortify supply resilience

Industry leaders must adopt pragmatic, prioritized actions to translate scientific progress into sustained patient impact. First, align translational science and clinical trial design with clear regulatory and payer evidence needs so that trials generate the data required for favorable reimbursement decisions. Second, implement robust supply continuity plans that include dual sourcing, local manufacturing assessments and validated contingency inventory levels to mitigate geopolitical and tariff-related risks. Third, pursue early and pragmatic payer engagement to establish value drivers, clarify acceptable endpoints and explore innovative contracting models that share risk across the value chain.

Additionally, companies should invest in companion diagnostic strategies that ensure accurate patient identification and support rapid trial enrollment, while integrating real-world evidence plans to capture effectiveness and safety in broader populations. Stakeholders should also prioritize cross-functional commercialization readiness, including provider education, patient support infrastructure and distribution channel optimization. By sequencing these recommendations-evidence alignment, supply resilience, payer engagement, diagnostic integration and commercialization preparedness-organizations can reduce execution risk and accelerate patient access to KRAS-targeted therapies.

Transparent research methodology detailing data sourcing, evidence synthesis, stakeholder interviews, clinical trial mapping and quality assurance protocols

The analysis underpinning this report integrates multiple evidence streams and follows a transparent methodology to ensure reliability and relevance. Primary inputs include peer-reviewed literature, publicly available regulatory documents, clinical-trial registries and company disclosures that inform program-level and mechanistic understanding. These sources are complemented by structured interviews with clinical investigators, manufacturing experts and commercial leaders to capture operational realities and forward-looking perspectives. In synthesizing these inputs, careful attention was given to cross-validation, privileging data points corroborated by multiple independent sources.

Analytical methods include qualitative evidence synthesis, clinical-trial mapping to identify enrollment drivers and endpoint trends, and scenario-based supply-chain sensitivity analysis that examines how operational disruptions or tariff changes could affect continuity. Throughout, quality assurance protocols were applied to ensure traceability of evidence and to document assumptions. This methodological approach provides a robust foundation for the insights and recommendations presented, balancing scientific rigor with pragmatic considerations relevant to decision-makers.

Concluding synthesis distilling scientific progress, clinical implications, commercialization readiness and strategic imperatives for KRAS investment and strategy

In summary, KRAS inhibitor development is at an inflection point where structural biology breakthroughs and refined clinical strategies are converging with commercial and operational imperatives. Scientific progress has made mutation-specific targeting feasible, but realizing patient impact requires integrated approaches that align trial design, manufacturing capability, payer engagement and regional entry strategies. Companies that successfully navigate these interconnected domains will convert translational advances into durable clinical programs and accessible therapies.

Moving forward, decision-makers should emphasize evidence that meets regulatory and payer expectations, build resilient supply chains that account for trade and tariff volatility, and tailor regional strategies to local regulatory and diagnostic environments. The path to broader KRAS-targeted care depends as much on disciplined execution and strategic partnerships as it does on further scientific innovation. With disciplined alignment across science, operations and commercialization, stakeholders can create a clear, actionable roadmap to deliver optimized therapies to the patients who need them most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. KRAS Inhibitor Market, by Indication

  • 8.1. Colorectal Cancer
  • 8.2. Non-Small Cell Lung Cancer
  • 8.3. Pancreatic Cancer

9. KRAS Inhibitor Market, by Mechanism Of Action

  • 9.1. Allosteric Inhibitors
  • 9.2. Covalent Inhibitors
  • 9.3. Non-Covalent Inhibitors

10. KRAS Inhibitor Market, by Mutation Type

  • 10.1. G12C
  • 10.2. G12D
  • 10.3. G12V

11. KRAS Inhibitor Market, by Dosage Form

  • 11.1. Injectable Solutions
  • 11.2. Oral Tablets

12. KRAS Inhibitor Market, by End User

  • 12.1. Cancer Care Centers
  • 12.2. Hospitals
  • 12.3. Retail Pharmacies
  • 12.4. Specialty Clinics

13. KRAS Inhibitor Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. KRAS Inhibitor Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. KRAS Inhibitor Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. KRAS Inhibitor Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States KRAS Inhibitor Market

18. China KRAS Inhibitor Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen
  • 19.6. AnBogen Therapeutics
  • 19.7. Applied Pharmaceutical Science
  • 19.8. AstraZeneca
  • 19.9. Biond Biologics
  • 19.10. Boehringer Ingelheim
  • 19.11. BridgeBio Oncology Therapeutics
  • 19.12. Bristol Myers Squibb
  • 19.13. Cardiff Oncology, Inc.
  • 19.14. Deciphera Pharmaceuticals
  • 19.15. Eli Lilly
  • 19.16. Elicio Therapeutics
  • 19.17. Erasca
  • 19.18. Frontier Medicines
  • 19.19. GenFleet Therapeutics
  • 19.20. Gritstone Bio
  • 19.21. Immuneering Corporation
  • 19.22. Innovent Bio
  • 19.23. InventisBio
  • 19.24. Jacobio Pharmaceuticals
  • 19.25. Jiangsu Hansoh Pharmaceutical
  • 19.26. Jiangsu Hengrui Medicine Co.
  • 19.27. Merck
  • 19.28. Mirati Therapeutics
  • 19.29. Novartis
  • 19.30. Quanta Therapeutics
  • 19.31. Revolution Medicines
  • 19.32. Roche
  • 19.33. Suzhou Zelgen Biopharmaceuticals
  • 19.34. Verastem Oncology

LIST OF FIGURES

  • FIGURE 1. GLOBAL KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL KRAS INHIBITOR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL KRAS INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL KRAS INHIBITOR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL KRAS INHIBITOR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL KRAS INHIBITOR MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL KRAS INHIBITOR MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL KRAS INHIBITOR MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL KRAS INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS KRAS INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL KRAS INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. GCC KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. GCC KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. GCC KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. GCC KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. G7 KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 148. G7 KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 150. G7 KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 155. NATO KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. NATO KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 157. NATO KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)